The aim of this study was to determine the effects of low-voltage electrochemotherapy with intraperitoneal cisplatin on hamster oral fibrosarcoma. Oral fibrosarcoma was transplanted submucosally into the cheek pouch mucosa of 100 hamsters. After transplantation, the hamsters were randomly divided into four equal groups. These groups received no treatment (D-E-); 2 mg/kg body weight cisplatin treatment without electroporation (D+E-); electroporation without cisplatin treatment (D-E+); or 2 mg/kg body weight cisplatin treatment followed by electroporation (D+E+). Electrical pulse treatment together with cisplatin injection markedly reduced the size of the tumour, whereas cisplatin injection or electrical pulse treatment alone did not. These results clearly indicate that the antitumour effect of cisplatin on hamster oral fibrosarcoma was considerably potentiated or enhanced by the administration of local electrical pulses at low voltages.
Introduction
In addition, the anti-tumour effectiveness of electrochemotherapy has been demonstrated in vivo in various tumour models in animals. 2 In electroporation, the electrical pulse temporarily alters the permeability of the cell membrane, allowing increased entry of anti-tumour agents into the cell. This has been demonstrated by data on increased drug concentrations in tumours, producing increased binding of the drug to DNA, after the application of electrical pulses. 3, 4 Electrochemotherapy has been shown to be effective in clinical settings. Several clinical trials of electrochemotherapy with either bleomycin or cisplatin have demonstrated its effectiveness in the treatment of head and neck tumours, basal cell carcinoma of the skin, malignant melanoma and adenocarcinoma. 5, 6 Since the drug concentration used in electrochemotherapy is low, drug-related sideeffects have not been reported so far. Although many experimental and clinical applications of high-voltage electrochemotherapy for tumours have been reported, low-voltage electrochemotherapy may be more desirable because of reduced electrical side-effects such as burning and oedema.
Cisplatin, a chemotherapeutic drug active against a wide spectrum of tumours, is used as a component of chemotherapy schedules for ovarian, head and neck, cervical, bladder, and small-cell and non-small-cell lung cancers. 7 The aim of this study was to examine the anti-tumour effects of lowvoltage electrochemotherapy with cisplatin in the treatment of hamster oral fibrosarcoma.
Materials and methods
Transplantable hamster oral fibrosarcoma, derived from a 9,10-dimethyl-1,2-benzanthracene-induced fibrosarcoma in the mandibular bone of Syrian golden hamsters, was used in this study. This oral fibrosarcoma has been maintained by serial transplantation into the cheek pouch of hamsters for over 85 generations. One hundred male 3-week-old Syrian golden hamsters were purchased from Japan SLC Co. Ltd (Hamamatsu, Japan). They were kept in a cage with free access to water and food during the entire experiment.
Oral fibrosarcoma was transplanted submucosally into the cheek pouch mucosa of all the hamsters. When tumour volumes had reached approximately 100 mm 3 , the hamsters were randomly divided into four equal groups of 25 and were used for the treatment experiments. All experimental protocols were in accordance with the regulations for animal care established by the Institutional Committee for Animal Care at our university.
TREATMENT SCHEDULES
The four groups of sarcoma-bearing animals were designated as D-E-(no treatment); D+E-(cisplatin treatment without electroporation); D-E+ (electroporation without cisplatin treatment); or D+E+ (cisplatin treatment followed by electroporation).
ELECTROPORATION
Electrical pulses were applied to the tumours using a CUY-21 electroporator (TR Tech Co. Ltd, Tokyo, Japan). Rectangular electrical pulses (field strength 50 V/cm, number of pulses 99, pulse duration 5 min, duty cycle 1 Hz) were delivered by two parallel stainless steel electrodes (length 15 mm, diameter 0.8 mm) inserted submucosally close to, and on both sides of, the tumour. Delivery was repeated three times from three directions at 60°intervals in the same plane.
In the D+E+ hamsters, electroporation was performed 30 min after cisplatin administration.
CISPLATIN TREATMENT
Cisplatin treatment consisted of an intraperitoneal injection of 2 mg/kg body weight cisplatin (Nihonkayaku Co. Ltd, Tokyo, Japan). This dose corresponds to roughly one-tenth of the median lethal dose (LD 50 ).
TUMOUR ASSESSMENT
The tumours in 40 of the hamsters (10 from each group) were measured by three people using a Vernier caliper every 2 days after the treatments were administered. Tumour volume was calculated using the equation:
where a, b and c were three mutually orthogonal measurements of the face of the nodule. The survival of these animals was monitored for a total period of 150 days.
Biopsies were taken from five animals from each group 2, 6 and 14 days posttreatment and examined histologically using light microscopy.
STATISTICAL ANALYSIS
Results were given as the mean ± SE, and were compared using the Kruskal-Wallis H test followed by the Student-Newman-Keuls test. A P-value < 0.05 was considered to be statistically significant.
Survival data were plotted as a survival curve using the Kaplan-Meier method.
Results
Tumours grew continuously in the D-E-, D+E-and D-E+ groups. The D+E+ group, which received electrical pulses and intraperitoneal injections of cisplatin, showed a significant reduction in tumour volume compared with the other groups (P < 0.01, Fig. 1 ). In the D+E+ group, the tumour volume gradually decreased up to 8 days after treatment and then started to increase again. In the D-E-, D+E-and D-E+ groups, the tumour volumes increased progressively. The rate of increase in tumour volume was significantly increased in these three groups compared with the D+E+ group (P < 0.01, Fig. 1 ). In addition, the growth of the tumours in the D+E-and D-E+ groups was significantly slowed compared with that in the D-E-group (P < 0.01, Fig. 1 ).
The Kaplan-Meier survival plot showed that hamsters in the D+E+ group survived significantly longer than those in the other three groups (P < 0.01, Fig. 2 ). In the D+E+ group, 70% of the hamsters were still alive 150 days after treatment; in the other three groups, all animals died within 82 days. 
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Histological examination revealed that the tumours of the D+E+ group were highly necrotic, with very few viable cells per high power field (Fig. 3A ) and many apoptotic cells (Fig. 3B) . In contrast, the untreated or partially treated hamsters had well-defined tumours.
No burns were observed on the animals exposed to electrical impulses; however, they did show signs of oedema for 2 days after the electrical treatment.
Discussion
Most recent studies of electrochemotherapy have used high voltages (1.0 KV/cm or more); however, some researchers 8 -10 have reported that low-voltage electrochemotherapy was effective. In a clinical setting, the use of low voltage is desirable to reduce the risk of tissue damage such as burns, oedema or erythema. The present study showed that low-voltage electrochemotherapy with intraperitoneal administration of cisplatin was an effective treatment of hamster oral fibrosarcoma, and was associated with few electrical side-effects.
In some previous studies, high-voltage electrochemotherapy has been used for the treatment of melanoma or other skin cancers, 5, 11, 12 with bleomycin as the anticancer agent. Bleomycin, which is hydrophilic and highly cytotoxic but cannot permeate cancer cells, was delivered by local injection into the tumour. Cisplatin has also been used in experimental 13, 14 and clinical 6, 15 applications of high-voltage electrochemotherapy for tumours. In the present study, tumour size was reduced and survival was extended in the D+E+ group. The dose of cisplatin used in this study was low, corresponding to roughly one-tenth of the LD 50 . This suggests that fibrosarcoma in humans might be treated with electrochemotherapy combined with a low dose of cisplatin, which is currently used in The theoretical basis for the current use of high-dose cisplatin comes from the low capability of cisplatin to permeate sarcoma cells. As electrochemotherapy with low-dose cisplatin was effective in the present study, this modality might also be suitable for older patients who are less tolerant of high-dose cisplatin treatment.
In this experiment, the proportion of apoptotic cells increased only after electrochemotherapy. Cisplatin is known to induce apoptotic cell death; therefore, it could be speculated that electrochemotherapy increased cisplatin delivery into the cells, producing apoptotic cell death. 16 The absence of apoptosis in the tumours treated with cisplatin alone is likely to be due to the low dose of cisplatin given. Further studies are needed to elucidate the mechanisms of cell death induced by electrochemotherapy with cisplatin.
This was the first study of the effects of low-voltage electrochemotherapy with low-dose cisplatin for oral fibrosarcoma. Systemic cisplatin administration and local electroporation had an extremely enhanced cytocidal effect on experimentally induced oral fibrosarcoma without electrical sideeffects. Low-voltage electrochemotherapy with low-dose cisplatin may be applicable to cases of fibrosarcoma and may contribute to improvements in the clinical outcome, although more extensive studies are necessary before this method can be applied clinically.
